Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,265
archived clinical trials in
Rheumatoid Arthritis

A Study in Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy
Status: Enrolling
Updated:  1/6/2016
Healthcare Research Consultant
mi
from
Tulsa, OK
A Study in Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy
Status: Enrolling
Updated: 1/6/2016
Healthcare Research Consultant
mi
from
Tulsa, OK
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy
Status: Enrolling
Updated:  1/6/2016
Oregon Health and Science University
mi
from
Portland, OR
A Study in Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy
Status: Enrolling
Updated: 1/6/2016
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy
Status: Enrolling
Updated:  1/6/2016
East Penn Rheumatology
mi
from
Bethlehem, PA
A Study in Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy
Status: Enrolling
Updated: 1/6/2016
East Penn Rheumatology
mi
from
Bethlehem, PA
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy
Status: Enrolling
Updated:  1/6/2016
Clinical Research Center of Reading, LLP
mi
from
Wyomissing, PA
A Study in Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy
Status: Enrolling
Updated: 1/6/2016
Clinical Research Center of Reading, LLP
mi
from
Wyomissing, PA
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy
Status: Enrolling
Updated:  1/6/2016
Carolina Rheumatology and Neurology Associates
mi
from
Myrtle Beach, SC
A Study in Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy
Status: Enrolling
Updated: 1/6/2016
Carolina Rheumatology and Neurology Associates
mi
from
Myrtle Beach, SC
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy
Status: Enrolling
Updated:  1/6/2016
Metroplex Clinical Research Center
mi
from
Dallas, TX
A Study in Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy
Status: Enrolling
Updated: 1/6/2016
Metroplex Clinical Research Center
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy
Status: Enrolling
Updated:  1/6/2016
Pioneer Research Solutions, Inc.
mi
from
Houston, TX
A Study in Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy
Status: Enrolling
Updated: 1/6/2016
Pioneer Research Solutions, Inc.
mi
from
Houston, TX
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy
Status: Enrolling
Updated:  1/6/2016
Accurate Clinical Research
mi
from
Houston, TX
A Study in Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy
Status: Enrolling
Updated: 1/6/2016
Accurate Clinical Research
mi
from
Houston, TX
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy
Status: Enrolling
Updated:  1/6/2016
Arthritis & Osteoporosis Associates, LLP
mi
from
Lubbock, TX
A Study in Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy
Status: Enrolling
Updated: 1/6/2016
Arthritis & Osteoporosis Associates, LLP
mi
from
Lubbock, TX
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy
Status: Enrolling
Updated:  1/6/2016
Accurate Clinical Research, Inc.
mi
from
Nassau Bay, TX
A Study in Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy
Status: Enrolling
Updated: 1/6/2016
Accurate Clinical Research, Inc.
mi
from
Nassau Bay, TX
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy
Status: Enrolling
Updated:  1/6/2016
Accurate Clinical Research
mi
from
Webster, TX
A Study in Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy
Status: Enrolling
Updated: 1/6/2016
Accurate Clinical Research
mi
from
Webster, TX
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy
Status: Enrolling
Updated:  1/6/2016
Center for Arthritis and Rheumatic Diseases
mi
from
Chesapeake, VA
A Study in Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy
Status: Enrolling
Updated: 1/6/2016
Center for Arthritis and Rheumatic Diseases
mi
from
Chesapeake, VA
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy
Status: Enrolling
Updated:  1/6/2016
The Seattle Arthritis Clinic
mi
from
Seattle, WA
A Study in Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy
Status: Enrolling
Updated: 1/6/2016
The Seattle Arthritis Clinic
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy
Status: Enrolling
Updated:  1/6/2016
The Vancouver Clinic
mi
from
Vancouver, WA
A Study in Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy
Status: Enrolling
Updated: 1/6/2016
The Vancouver Clinic
mi
from
Vancouver, WA
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy
Status: Enrolling
Updated:  1/6/2016
Rheumatology and Immunotherapy Center
mi
from
Franklin, WI
A Study in Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy
Status: Enrolling
Updated: 1/6/2016
Rheumatology and Immunotherapy Center
mi
from
Franklin, WI
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy
Status: Enrolling
Updated:  1/6/2016
Research Site
mi
from
Bahía Blanca,
A Study in Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy
Status: Enrolling
Updated: 1/6/2016
Research Site
mi
from
Bahía Blanca,
Click here to add this to my saved trials
To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)
An Open-label, Randomized, Parallel Group Study Assessing the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Active Rheumatoid Arthritis
Status: Enrolling
Updated:  1/6/2016
Clinical Research Facility
mi
from
Gilbert, AZ
To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)
An Open-label, Randomized, Parallel Group Study Assessing the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Active Rheumatoid Arthritis
Status: Enrolling
Updated: 1/6/2016
Clinical Research Facility
mi
from
Gilbert, AZ
Click here to add this to my saved trials
To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)
An Open-label, Randomized, Parallel Group Study Assessing the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Active Rheumatoid Arthritis
Status: Enrolling
Updated:  1/6/2016
Clinical Research Facility
mi
from
Upland, CA
To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)
An Open-label, Randomized, Parallel Group Study Assessing the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Active Rheumatoid Arthritis
Status: Enrolling
Updated: 1/6/2016
Clinical Research Facility
mi
from
Upland, CA
Click here to add this to my saved trials
To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)
An Open-label, Randomized, Parallel Group Study Assessing the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Active Rheumatoid Arthritis
Status: Enrolling
Updated:  1/6/2016
Clinical Research Facility
mi
from
South Miami, FL
To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)
An Open-label, Randomized, Parallel Group Study Assessing the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Active Rheumatoid Arthritis
Status: Enrolling
Updated: 1/6/2016
Clinical Research Facility
mi
from
South Miami, FL
Click here to add this to my saved trials
To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)
An Open-label, Randomized, Parallel Group Study Assessing the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Active Rheumatoid Arthritis
Status: Enrolling
Updated:  1/6/2016
Clinical Research Facility
mi
from
Elizabethtown, KY
To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)
An Open-label, Randomized, Parallel Group Study Assessing the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Active Rheumatoid Arthritis
Status: Enrolling
Updated: 1/6/2016
Clinical Research Facility
mi
from
Elizabethtown, KY
Click here to add this to my saved trials
To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)
An Open-label, Randomized, Parallel Group Study Assessing the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Active Rheumatoid Arthritis
Status: Enrolling
Updated:  1/6/2016
Clinical Research Facility
mi
from
Minot, ND
To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)
An Open-label, Randomized, Parallel Group Study Assessing the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Active Rheumatoid Arthritis
Status: Enrolling
Updated: 1/6/2016
Clinical Research Facility
mi
from
Minot, ND
Click here to add this to my saved trials
To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)
An Open-label, Randomized, Parallel Group Study Assessing the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Active Rheumatoid Arthritis
Status: Enrolling
Updated:  1/6/2016
Clinical Research Facility
mi
from
Oklahoma City, OK
To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)
An Open-label, Randomized, Parallel Group Study Assessing the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Active Rheumatoid Arthritis
Status: Enrolling
Updated: 1/6/2016
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)
An Open-label, Randomized, Parallel Group Study Assessing the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Active Rheumatoid Arthritis
Status: Enrolling
Updated:  1/6/2016
Clinical Research Facility
mi
from
Tulsa, OK
To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)
An Open-label, Randomized, Parallel Group Study Assessing the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Active Rheumatoid Arthritis
Status: Enrolling
Updated: 1/6/2016
Clinical Research Facility
mi
from
Tulsa, OK
Click here to add this to my saved trials
To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)
An Open-label, Randomized, Parallel Group Study Assessing the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Active Rheumatoid Arthritis
Status: Enrolling
Updated:  1/6/2016
Clinical Research Facility
mi
from
Duncansville, PA
To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)
An Open-label, Randomized, Parallel Group Study Assessing the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Active Rheumatoid Arthritis
Status: Enrolling
Updated: 1/6/2016
Clinical Research Facility
mi
from
Duncansville, PA
Click here to add this to my saved trials
To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)
An Open-label, Randomized, Parallel Group Study Assessing the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Active Rheumatoid Arthritis
Status: Enrolling
Updated:  1/6/2016
Clinical Research Facility
mi
from
Jackson, TN
To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)
An Open-label, Randomized, Parallel Group Study Assessing the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Active Rheumatoid Arthritis
Status: Enrolling
Updated: 1/6/2016
Clinical Research Facility
mi
from
Jackson, TN
Click here to add this to my saved trials
To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)
An Open-label, Randomized, Parallel Group Study Assessing the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Active Rheumatoid Arthritis
Status: Enrolling
Updated:  1/6/2016
Clinical Research Facility
mi
from
Amarillo, TX
To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)
An Open-label, Randomized, Parallel Group Study Assessing the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Active Rheumatoid Arthritis
Status: Enrolling
Updated: 1/6/2016
Clinical Research Facility
mi
from
Amarillo, TX
Click here to add this to my saved trials
To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)
An Open-label, Randomized, Parallel Group Study Assessing the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Active Rheumatoid Arthritis
Status: Enrolling
Updated:  1/6/2016
Clinical Research Facility
mi
from
Mesquite, TX
To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)
An Open-label, Randomized, Parallel Group Study Assessing the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Active Rheumatoid Arthritis
Status: Enrolling
Updated: 1/6/2016
Clinical Research Facility
mi
from
Mesquite, TX
Click here to add this to my saved trials
To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)
An Open-label, Randomized, Parallel Group Study Assessing the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Active Rheumatoid Arthritis
Status: Enrolling
Updated:  1/6/2016
Clinical Research Facility
mi
from
Clarksburg, WV
To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)
An Open-label, Randomized, Parallel Group Study Assessing the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Active Rheumatoid Arthritis
Status: Enrolling
Updated: 1/6/2016
Clinical Research Facility
mi
from
Clarksburg, WV
Click here to add this to my saved trials
To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)
An Open-label, Randomized, Parallel Group Study Assessing the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Active Rheumatoid Arthritis
Status: Enrolling
Updated:  1/6/2016
Clinical Research Facility
mi
from
Franklin, WI
To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)
An Open-label, Randomized, Parallel Group Study Assessing the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Active Rheumatoid Arthritis
Status: Enrolling
Updated: 1/6/2016
Clinical Research Facility
mi
from
Franklin, WI
Click here to add this to my saved trials
To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)
An Open-label, Randomized, Parallel Group Study Assessing the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Active Rheumatoid Arthritis
Status: Enrolling
Updated:  1/6/2016
mi
from
Santiago,
To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)
An Open-label, Randomized, Parallel Group Study Assessing the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Active Rheumatoid Arthritis
Status: Enrolling
Updated: 1/6/2016
mi
from
Santiago,
Click here to add this to my saved trials
Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis
A 24-week Phase IIb, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Tregalizumab (BT061) in Combination With Methotrexate in the Treatment of Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Alone, Followed by a 24-week Extension Phase: T Cell REgulating Arthritis Trial 2b (TREAT 2b)
Status: Enrolling
Updated:  1/11/2016
Study Site 07
mi
from
Paradise Valley, AZ
Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis
A 24-week Phase IIb, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Tregalizumab (BT061) in Combination With Methotrexate in the Treatment of Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Alone, Followed by a 24-week Extension Phase: T Cell REgulating Arthritis Trial 2b (TREAT 2b)
Status: Enrolling
Updated: 1/11/2016
Study Site 07
mi
from
Paradise Valley, AZ
Click here to add this to my saved trials
Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis
A 24-week Phase IIb, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Tregalizumab (BT061) in Combination With Methotrexate in the Treatment of Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Alone, Followed by a 24-week Extension Phase: T Cell REgulating Arthritis Trial 2b (TREAT 2b)
Status: Enrolling
Updated:  1/11/2016
Study Site 01
mi
from
Springfield, IL
Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis
A 24-week Phase IIb, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Tregalizumab (BT061) in Combination With Methotrexate in the Treatment of Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Alone, Followed by a 24-week Extension Phase: T Cell REgulating Arthritis Trial 2b (TREAT 2b)
Status: Enrolling
Updated: 1/11/2016
Study Site 01
mi
from
Springfield, IL
Click here to add this to my saved trials
Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis
A 24-week Phase IIb, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Tregalizumab (BT061) in Combination With Methotrexate in the Treatment of Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Alone, Followed by a 24-week Extension Phase: T Cell REgulating Arthritis Trial 2b (TREAT 2b)
Status: Enrolling
Updated:  1/11/2016
Study Site 03
mi
from
Lincoln, NE
Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis
A 24-week Phase IIb, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Tregalizumab (BT061) in Combination With Methotrexate in the Treatment of Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Alone, Followed by a 24-week Extension Phase: T Cell REgulating Arthritis Trial 2b (TREAT 2b)
Status: Enrolling
Updated: 1/11/2016
Study Site 03
mi
from
Lincoln, NE
Click here to add this to my saved trials
Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis
A 24-week Phase IIb, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Tregalizumab (BT061) in Combination With Methotrexate in the Treatment of Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Alone, Followed by a 24-week Extension Phase: T Cell REgulating Arthritis Trial 2b (TREAT 2b)
Status: Enrolling
Updated:  1/11/2016
Study Site 02
mi
from
Clifton, NJ
Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis
A 24-week Phase IIb, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Tregalizumab (BT061) in Combination With Methotrexate in the Treatment of Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Alone, Followed by a 24-week Extension Phase: T Cell REgulating Arthritis Trial 2b (TREAT 2b)
Status: Enrolling
Updated: 1/11/2016
Study Site 02
mi
from
Clifton, NJ
Click here to add this to my saved trials
Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis
A 24-week Phase IIb, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Tregalizumab (BT061) in Combination With Methotrexate in the Treatment of Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Alone, Followed by a 24-week Extension Phase: T Cell REgulating Arthritis Trial 2b (TREAT 2b)
Status: Enrolling
Updated:  1/11/2016
Study Site 04
mi
from
North Charleston, SC
Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis
A 24-week Phase IIb, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Tregalizumab (BT061) in Combination With Methotrexate in the Treatment of Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Alone, Followed by a 24-week Extension Phase: T Cell REgulating Arthritis Trial 2b (TREAT 2b)
Status: Enrolling
Updated: 1/11/2016
Study Site 04
mi
from
North Charleston, SC
Click here to add this to my saved trials
Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis
A 24-week Phase IIb, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Tregalizumab (BT061) in Combination With Methotrexate in the Treatment of Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Alone, Followed by a 24-week Extension Phase: T Cell REgulating Arthritis Trial 2b (TREAT 2b)
Status: Enrolling
Updated:  1/11/2016
Study Site 05
mi
from
Jackson, TN
Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis
A 24-week Phase IIb, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Tregalizumab (BT061) in Combination With Methotrexate in the Treatment of Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Alone, Followed by a 24-week Extension Phase: T Cell REgulating Arthritis Trial 2b (TREAT 2b)
Status: Enrolling
Updated: 1/11/2016
Study Site 05
mi
from
Jackson, TN
Click here to add this to my saved trials
Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis
A 24-week Phase IIb, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Tregalizumab (BT061) in Combination With Methotrexate in the Treatment of Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Alone, Followed by a 24-week Extension Phase: T Cell REgulating Arthritis Trial 2b (TREAT 2b)
Status: Enrolling
Updated:  1/11/2016
Study Site 09
mi
from
Houston, TX
Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis
A 24-week Phase IIb, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Tregalizumab (BT061) in Combination With Methotrexate in the Treatment of Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Alone, Followed by a 24-week Extension Phase: T Cell REgulating Arthritis Trial 2b (TREAT 2b)
Status: Enrolling
Updated: 1/11/2016
Study Site 09
mi
from
Houston, TX
Click here to add this to my saved trials
Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis
A 24-week Phase IIb, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Tregalizumab (BT061) in Combination With Methotrexate in the Treatment of Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Alone, Followed by a 24-week Extension Phase: T Cell REgulating Arthritis Trial 2b (TREAT 2b)
Status: Enrolling
Updated:  1/11/2016
Study Site 10
mi
from
Katy, TX
Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis
A 24-week Phase IIb, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Tregalizumab (BT061) in Combination With Methotrexate in the Treatment of Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Alone, Followed by a 24-week Extension Phase: T Cell REgulating Arthritis Trial 2b (TREAT 2b)
Status: Enrolling
Updated: 1/11/2016
Study Site 10
mi
from
Katy, TX
Click here to add this to my saved trials
Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis
A 24-week Phase IIb, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Tregalizumab (BT061) in Combination With Methotrexate in the Treatment of Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Alone, Followed by a 24-week Extension Phase: T Cell REgulating Arthritis Trial 2b (TREAT 2b)
Status: Enrolling
Updated:  1/11/2016
Study Site 01
mi
from
Plovdiv,
Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis
A 24-week Phase IIb, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Tregalizumab (BT061) in Combination With Methotrexate in the Treatment of Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Alone, Followed by a 24-week Extension Phase: T Cell REgulating Arthritis Trial 2b (TREAT 2b)
Status: Enrolling
Updated: 1/11/2016
Study Site 01
mi
from
Plovdiv,
Click here to add this to my saved trials
A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I)
A Randomized, Double-blind, Placebo-controlled, Multicentre, Phase II Dose-finding Study of Atacicept Given Subcutaneously in Subjects With Rheumatoid Arthritis and Inadequate Response to TNFa Antagonist Therapy
Status: Enrolling
Updated:  1/19/2016
EMD Serono, Inc.
mi
from
Rockland, MA
A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I)
A Randomized, Double-blind, Placebo-controlled, Multicentre, Phase II Dose-finding Study of Atacicept Given Subcutaneously in Subjects With Rheumatoid Arthritis and Inadequate Response to TNFa Antagonist Therapy
Status: Enrolling
Updated: 1/19/2016
EMD Serono, Inc.
mi
from
Rockland, MA
Click here to add this to my saved trials
A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I)
A Randomized, Double-blind, Placebo-controlled, Multicentre, Phase II Dose-finding Study of Atacicept Given Subcutaneously in Subjects With Rheumatoid Arthritis and Inadequate Response to TNFa Antagonist Therapy
Status: Enrolling
Updated:  1/19/2016
Merck/Serono
mi
from
Canada,
A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I)
A Randomized, Double-blind, Placebo-controlled, Multicentre, Phase II Dose-finding Study of Atacicept Given Subcutaneously in Subjects With Rheumatoid Arthritis and Inadequate Response to TNFa Antagonist Therapy
Status: Enrolling
Updated: 1/19/2016
Merck/Serono
mi
from
Canada,
Click here to add this to my saved trials
Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)
A Randomised, Double-blind, Placebo Controlled, Multi-centre Phase II Study of Atacicept in Anti-TNFα-naïve Patients With Moderate to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Status: Enrolling
Updated:  1/19/2016
Please Contact US Medical Information
mi
from
Rockland, MA
Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)
A Randomised, Double-blind, Placebo Controlled, Multi-centre Phase II Study of Atacicept in Anti-TNFα-naïve Patients With Moderate to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Status: Enrolling
Updated: 1/19/2016
Please Contact US Medical Information
mi
from
Rockland, MA
Click here to add this to my saved trials
Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)
A Randomised, Double-blind, Placebo Controlled, Multi-centre Phase II Study of Atacicept in Anti-TNFα-naïve Patients With Moderate to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Status: Enrolling
Updated:  1/19/2016
Please contact the Merck KGaA Communication Center
mi
from
Darmstadt,
Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)
A Randomised, Double-blind, Placebo Controlled, Multi-centre Phase II Study of Atacicept in Anti-TNFα-naïve Patients With Moderate to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Status: Enrolling
Updated: 1/19/2016
Please contact the Merck KGaA Communication Center
mi
from
Darmstadt,
Click here to add this to my saved trials
Cementless Alumina-Alumina Total Hip and Hybrid
Keramos Ceramic/Ceramic Total Hip System
Status: Enrolling
Updated:  1/19/2016
Mark Newman, Inc.
mi
from
Newport Beach, CA
Cementless Alumina-Alumina Total Hip and Hybrid
Keramos Ceramic/Ceramic Total Hip System
Status: Enrolling
Updated: 1/19/2016
Mark Newman, Inc.
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Cementless Alumina-Alumina Total Hip and Hybrid
Keramos Ceramic/Ceramic Total Hip System
Status: Enrolling
Updated:  1/19/2016
Charleston Orthopaedic Assoc.
mi
from
Charleston, SC
Cementless Alumina-Alumina Total Hip and Hybrid
Keramos Ceramic/Ceramic Total Hip System
Status: Enrolling
Updated: 1/19/2016
Charleston Orthopaedic Assoc.
mi
from
Charleston, SC
Click here to add this to my saved trials
Cementless Alumina-Alumina Total Hip and Hybrid
Keramos Ceramic/Ceramic Total Hip System
Status: Enrolling
Updated:  1/19/2016
Advanced Orthopaedic Centers
mi
from
Richmond, VA
Cementless Alumina-Alumina Total Hip and Hybrid
Keramos Ceramic/Ceramic Total Hip System
Status: Enrolling
Updated: 1/19/2016
Advanced Orthopaedic Centers
mi
from
Richmond, VA
Click here to add this to my saved trials
A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®)
A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®)
Status: Enrolling
Updated:  1/21/2016
Clinical Research Facility
mi
from
Birmingham, AL
A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®)
A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®)
Status: Enrolling
Updated: 1/21/2016
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®)
A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®)
Status: Enrolling
Updated:  1/21/2016
Clinical Research Facility
mi
from
Huntsville, AL
A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®)
A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®)
Status: Enrolling
Updated: 1/21/2016
Clinical Research Facility
mi
from
Huntsville, AL
Click here to add this to my saved trials
A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®)
A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®)
Status: Enrolling
Updated:  1/21/2016
Clinical Research Facility
mi
from
Peoria, AZ
A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®)
A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®)
Status: Enrolling
Updated: 1/21/2016
Clinical Research Facility
mi
from
Peoria, AZ
Click here to add this to my saved trials
A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®)
A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®)
Status: Enrolling
Updated:  1/21/2016
Clinical Research Facility
mi
from
Phoenix, AZ
A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®)
A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®)
Status: Enrolling
Updated: 1/21/2016
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials